Subconjunctival Delivery of p75NTR Antagonists Reduces the Inflammatory, Vascular, and Neurodegenerative Pathologies of Diabetic Retinopathy | Zendy

Alba Galán | Zendy; Pablo F. Barcelona | Zendy; Hinyu Nedev | Zendy; Marinko V. Šarunic | Zendy; Yifan Jian | Zendy; H. Uri Saragovi | Zendy

Open Access

Subconjunctival Delivery of p75^NTR Antagonists Reduces the Inflammatory, Vascular, and Neurodegenerative Pathologies of Diabetic Retinopathy

Author(s) -

Alba Galán,

Pablo F. Barcelona,

Hinyu Nedev,

Marinko V. Šarunic,

Yifan Jian,

H. Uri Saragovi

Publication year - 2017

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.16-20988

Subject(s) - diabetic retinopathy , medicine , retinal , inflammation , drug delivery , pharmacology , edema , retina , drug , therapeutic effect , uveitis , ophthalmology , diabetes mellitus , immunology , endocrinology , neuroscience , chemistry , organic chemistry , biology

The p75NTR is a novel therapeutic target validated in a streptozotocin mouse model of diabetic retinopathy. Intravitreal (IVT) injection of small molecule p75NTR antagonist THX-B was therapeutic and resolved the inflammatory, vascular, and neurodegenerative phases of the retinal pathology. To simplify clinical translation, we sought a superior drug delivery method that circumvents risks associated with IVT injections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research